https://www.selleckchem.com/pr....oducts/cx-4945-silmi
To evaluate the efficacy of bevacizumab a monoclonal, antivascular endothelial growth factor antibody in combination with cytotoxic chemotherapy in Turkish patients with recurrent and metastatic cervical cancer. Data of 64 patients with metastatic or recurrent cervical cancer, receiving bevacizumab with first-line cisplatin or carboplatin and paclitaxel chemotherapy between 2013 and 2017 were retrospectively evaluated. The mean age of the patients was 49 years (range, 28-68), the median follow-up time was 12 months (range,
Like
Comment
Share
